


## EXPERIMENTAL ARTHRITIS

# Antihistamines as treatments for autoimmune disease?



H&E staining of paws from mice with CIA. Reduced inflammation and damage is evident in the H<sub>4</sub>R-antagonist-treated mouse versus the vehicle-treated mouse. Image courtesy of Robin L. Thurmond.

Research from San Diego, published in the *Annals of the Rheumatic Diseases*, shows that histamine is not only involved in allergies but that it also has a role in potentiating inflammation in experimental inflammatory arthritis. As Robin Thurmond, the lead author on this paper explains: “There has been literature showing that histamine appears to be increased in arthritic joints, but I think this was dismissed as being unimportant. Our work shows that histamine, acting via the H<sub>4</sub> receptor, amplifies both the innate and adaptive immune responses that underlie the disease.”

The researchers investigated the role of histamine<sub>4</sub> receptor (H<sub>4</sub>R) in the development of autoimmune arthritis (CAIA; collagen antibody-induced arthritis) and inflammatory arthritis (CIA, collagen-induced arthritis) in studies involving H<sub>4</sub>R-deficient mice or an H<sub>4</sub>R antagonist (JNJ 28307474).

In the CAIA model, H<sub>4</sub>R-deficient and H<sub>4</sub>R-antagonist-treated mice developed less severe disease than the wild-type or vehicle-treated mice; disease scores were lower, and levels of inflammation, pannus formation, and bone and cartilage damage were reduced. Similar results were seen in the CIA model. Treatment with the H<sub>4</sub>R antagonist resulted in a dose-dependent reduction in disease severity compared with vehicle-treated mice, as confirmed by histological examination (see figure). Of 12

H<sub>4</sub>R-deficient mice, only seven developed inflammatory arthritis (score >2) in comparison with the wild-type mice who all developed disease. After 14 days, two of the H<sub>4</sub>R-deficient mice had fully recovered (score <2), whereas the disease scores remained unchanged in the wild-type mice. Disease severity in wild-type mice with established disease was reduced after treatment with an H<sub>4</sub>R-receptor antagonist.

These findings indicate a role for histamine, via the H<sub>4</sub>R, in the pathogenesis of experimental inflammatory arthritis, but how might H<sub>4</sub>R mediate its effects? The authors discovered that, in the CIA model, animals with disease had more lymph nodal IL-17<sup>+</sup> CD4<sup>+</sup> T cells than healthy mice and that treatment with an H<sub>4</sub>R antagonist reduced the number of these cells and the level of IL-17 produced. Therefore, H<sub>4</sub>R might, in part, act by influencing type 17 T helper cells.

“If the preclinical data translates into clinical efficacy, targeting H<sub>4</sub>R may provide novel oral treatment options for patients with RA,” states Thurmond. He concludes: “H<sub>4</sub>R antagonists may become the antihistamines for autoimmune diseases.”

*Jenny Buckland*

**Original article** Cowden, J. M. et al. The histamine H<sub>4</sub> receptor mediates inflammation and Th17 responses in preclinical models of arthritis. *Ann. Rheum. Dis.* doi:10.1136/annrheumdis-2013-203832